^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD5863

    i
    Other names: AZD5863, HBM7022
    Company:
    AstraZeneca, Harbour BioMed
    Drug class:
    CD3 agonist, CLDN18.2 inhibitor
    Related drugs:
    9ms
    Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, AstraZeneca
    New P1/2 trial • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    AZD5863